ArticleIJID regions2025
Seroprevalence of varicella zoster virus in Colombia: A community-based mixture models study.
Article in IJID regions, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: To describe the distribution of immunoglobulin (Ig) G antibodies against varicella by sociodemographic characteristics during the period before vaccination in Medellín, Antioquia, Colombia. Methods: A population seroprevalence based on a previous study carried out in men and women aged 6-64 years, residing in the urban and rural zone of Medellín, Antioquia, Colombia in 2009. A probability sample of 2124 individuals was selected using a multistage sampling design. IgG antibodies against varicella zoster virus were determined in human serum/plasma by an enzyme-linked immunosorbent assay test. Global seroprevalence levels were calculated, considering a sample expansion factor, allowing inference to the population. Antibody distribution was explored worldwide by sex and zone of residence, using finite mixture models. Results: Global seropositivity was 85.9% (95% confidence interval [CI]: 82.9-88.5) using the manufacturer's cutoff and 81.5% (95% CI: 78.0-88.5) using the complete data from antibody distribution. Significant seronegativity was detected in the group from 6 to 17 years of age of 20.6% (95% CI: 14.8-27.9), without differences by sex and zone of residence. Conclusions: The seronegativity in the 6-17 age group shows the need to periodically monitor antibody prevalence in children and young people to guide new vaccination and transmission prevention strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.